Our objective was to explore the Odds Ratios (OR) associated with all-grade and grade 3–5 CIP in patients with advanced NSCLC undergoing treatment with PD-1/PDL-1 or CTLA-4 inhibitors. The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.